ARGX — argenx SE
$960.04
$-21.29 (-2.17%)
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Market Cap
$60.37B
Forward P/E
28.8x
52-Week Range
N/A
ARGX Price History
Revenue vs. Net Income
$4.2B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$574M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
17.4%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
6.4x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
2.6%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+1.3%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
